CMSC Initiates Coverage on JIANGXI BIO with "Accumulate" Rating and HK$23.6 Target Price

Stock News10:27

CMSC has published a research report initiating coverage on JIANGXI BIO (06915) with an "Accumulate" rating and a target price of HK$23.6. The brokerage highlights that the company is accelerating its transformation from a dominant player in the single tetanus antitoxin (TAT) market to a comprehensive antiserum platform, with its pipeline focused on rigid demand areas facing severe supply shortages, which is expected to enter a harvest phase soon.

The report notes that JIANGXI BIO is the world's largest supplier and exporter of human-use TAT and one of the few antiserum companies in China with a fully integrated value chain spanning animal husbandry, antigen immunization, plasma collection, antibody purification, and formulation production. Investors are advised to pay attention to its long-term investment value as a hidden champion in the antiserum sector.

CMSC projects the company's revenue to grow by 28%, 53%, and 56% year-over-year from 2026 to 2028, respectively. The growth is driven by the launch of the next-generation TAT in 2025, which is expected to boost average selling prices, along with deeper domestic volume-based procurement and a recovery in overseas exports. Additionally, starting in 2026, the veterinary drug segment is set to scale up systematically, with adjusted net profit forecast at RMB 140 million for 2028.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173344381?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 10:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173344381","market":"other","top_or_hot":-1,"title":"CMSC Initiates Coverage on JIANGXI BIO with \"Accumulate\" Rating and HK$23.6 Target Price","media":"Stock News","content":"<p>CMSC has published a research report initiating coverage on <b>JIANGXI BIO</b> (06915) with an \"Accumulate\" rating and a target price of HK$23.6. The brokerage highlights that the company is accelerating its transformation from a dominant player in the single tetanus antitoxin (TAT) market to a comprehensive antiserum platform, with its pipeline focused on rigid demand areas facing severe supply shortages, which is expected to enter a harvest phase soon.<br><br>The report notes that <b>JIANGXI BIO</b> is the world's largest supplier and exporter of human-use TAT and one of the few antiserum companies in China with a fully integrated value chain spanning animal husbandry, antigen immunization, plasma collection, antibody purification, and formulation production. Investors are advised to pay attention to its long-term investment value as a hidden champion in the antiserum sector.<br><br>CMSC projects the company's revenue to grow by 28%, 53%, and 56% year-over-year from 2026 to 2028, respectively. The growth is driven by the launch of the next-generation TAT in 2025, which is expected to boost average selling prices, along with deeper domestic volume-based procurement and a recovery in overseas exports. Additionally, starting in 2026, the veterinary drug segment is set to scale up systematically, with adjusted net profit forecast at RMB 140 million for 2028.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CMSC Initiates Coverage on JIANGXI BIO with \"Accumulate\" Rating and HK$23.6 Target Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCMSC Initiates Coverage on JIANGXI BIO with \"Accumulate\" Rating and HK$23.6 Target Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-20 10:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CMSC has published a research report initiating coverage on <b>JIANGXI BIO</b> (06915) with an \"Accumulate\" rating and a target price of HK$23.6. The brokerage highlights that the company is accelerating its transformation from a dominant player in the single tetanus antitoxin (TAT) market to a comprehensive antiserum platform, with its pipeline focused on rigid demand areas facing severe supply shortages, which is expected to enter a harvest phase soon.<br><br>The report notes that <b>JIANGXI BIO</b> is the world's largest supplier and exporter of human-use TAT and one of the few antiserum companies in China with a fully integrated value chain spanning animal husbandry, antigen immunization, plasma collection, antibody purification, and formulation production. Investors are advised to pay attention to its long-term investment value as a hidden champion in the antiserum sector.<br><br>CMSC projects the company's revenue to grow by 28%, 53%, and 56% year-over-year from 2026 to 2028, respectively. The growth is driven by the launch of the next-generation TAT in 2025, which is expected to boost average selling prices, along with deeper domestic volume-based procurement and a recovery in overseas exports. Additionally, starting in 2026, the veterinary drug segment is set to scale up systematically, with adjusted net profit forecast at RMB 140 million for 2028.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1173344381","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173344381","pubTimestamp":1787192844,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CMSC has published a research report initiating coverage on JIANGXI BIO (06915) with an \"Accumulate\" rating and a target price of HK$23.6. The brokerage highlights that the company is accelerating...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","EWH":"香港ETF-iShares MSCI","BK1147":"投资银行业与经纪业","BK1564":"中资券商股","06099":"招商证券","06915":"江西生物"},"translate_title":"CMSC开始对江西生物进行“累积”评级，目标价23.6港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06099":1,"EWH":1,"06915":1},"content_text":"CMSC has published a research report initiating coverage on JIANGXI BIO (06915) with an \"Accumulate\" rating and a target price of HK$23.6. The brokerage highlights that the company is accelerating its transformation from a dominant player in the single tetanus antitoxin (TAT) market to a comprehensive antiserum platform, with its pipeline focused on rigid demand areas facing severe supply shortages, which is expected to enter a harvest phase soon.The report notes that JIANGXI BIO is the world's largest supplier and exporter of human-use TAT and one of the few antiserum companies in China with a fully integrated value chain spanning animal husbandry, antigen immunization, plasma collection, antibody purification, and formulation production. Investors are advised to pay attention to its long-term investment value as a hidden champion in the antiserum sector.CMSC projects the company's revenue to grow by 28%, 53%, and 56% year-over-year from 2026 to 2028, respectively. The growth is driven by the launch of the next-generation TAT in 2025, which is expected to boost average selling prices, along with deeper domestic volume-based procurement and a recovery in overseas exports. Additionally, starting in 2026, the veterinary drug segment is set to scale up systematically, with adjusted net profit forecast at RMB 140 million for 2028.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173344381","isCrawlerRequest":true}